Trial Profile
An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2013
Price :
$35
*
At a glance
- Drugs Maveropepimut-S (Primary) ; Eftilagimod alpha
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROVAX
- 09 Oct 2013 New trial record